Oral chemotherapy metric performance in quality oncology practice initiative practices: Updated trends and analysis Journal Article


Authors: Blinder, V. S.; Garrett-Mayer, E.; Jacobsen, P. B.; Kozlik, M. M.; Markham, M. J.; Siegel, R. D.; Kamal, A. H.; Crist, S. T. S.; Rosenthal, J.; Chiang, A. C.; on behalf of the, Asco Quality Publications Task Force
Article Title: Oral chemotherapy metric performance in quality oncology practice initiative practices: Updated trends and analysis
Abstract: Background: Oral chemotherapy performance measures were first introduced into ASCO’s Quality Oncology Practice Initiative (QOPI) in 2013. This study examined performance on these measures among QOPI-participating practices and evaluated whether it differed among practices based on meeting QOPI Certification Program standards. Methods: A total of 192 QOPI-participating practices (certified, n550 [26%]; not certified, n5142 [74%]) reported performance on oral chemotherapy measures in 2017 and 2018. Inclusion was limited to practices reporting on $3 charts for $1 oral chemotherapy measure. Performance was defined as the percentage of charts examined that adhered to the measure. Descriptive analyses were used to characterize performance within and across practices, and mixed-effects logistic regression models were conducted to compare performance based on certification status. Results: Median performance across practices for the 9 oral chemotherapy measures examined ranged from 44% (education before the start of treatment addressing missed doses, toxicities, and clinical contact instructions [composite measure]) to 100% (documented dose, documented plan, and education about toxicities). Certified practices were more likely to provide education about clinic contact instructions than noncertified practices (odds ratio, 4.87; 95% CI, 1.00–24.0). Performance on all other measures was not significantly associated with certification status. Conclusions: There is wide variability in quality related to performance on oral chemotherapy measures across all QOPI-participating practices, and several areas were identified in which administration of oral chemotherapy could be improved. Our findings highlight the need for the development and implementation of appropriate standards that apply to oral chemotherapy and address the complexities that set it apart from parenteral treatment. © 2022 Harborside Press. All rights reserved.
Keywords: cancer chemotherapy; major clinical study; antineoplastic agent; clinical practice; oncology; medical oncology; cross-sectional study; administration, oral; certification; performance; oral drug administration; humans; human; article
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 20
Issue: 10
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2022-10-01
Start Page: 1099
End Page: 1106
Language: English
DOI: 10.6004/jnccn.2022.7024
PUBMED: 36240846
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 November 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Victoria Susana Blinder
    112 Blinder